463 related articles for article (PubMed ID: 28867159)
1. New Insights into the Nuclear Imaging Phenotypes of Cluster 1 Pheochromocytoma and Paraganglioma.
Taïeb D; Pacak K
Trends Endocrinol Metab; 2017 Nov; 28(11):807-817. PubMed ID: 28867159
[TBL] [Abstract][Full Text] [Related]
2. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
[TBL] [Abstract][Full Text] [Related]
3. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography.
Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Eisenhofer G; King KS; Rao JU; Wesley RA; Adams KT; Pacak K
J Natl Cancer Inst; 2012 May; 104(9):700-8. PubMed ID: 22517990
[TBL] [Abstract][Full Text] [Related]
4. Significance of Alpha-inhibin Expression in Pheochromocytomas and Paragangliomas.
Mete O; Pakbaz S; Lerario AM; Giordano TJ; Asa SL
Am J Surg Pathol; 2021 Sep; 45(9):1264-1273. PubMed ID: 33826547
[TBL] [Abstract][Full Text] [Related]
5. Current and future anatomical and functional imaging approaches to pheochromocytoma and paraganglioma.
Timmers HJ; Taieb D; Pacak K
Horm Metab Res; 2012 May; 44(5):367-72. PubMed ID: 22399235
[TBL] [Abstract][Full Text] [Related]
6. Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups.
Taïeb D; Jha A; Treglia G; Pacak K
Endocr Relat Cancer; 2019 Nov; 26(11):R627-R652. PubMed ID: 31561209
[TBL] [Abstract][Full Text] [Related]
7. The connection between tricarboxylic acid cycle enzyme mutations and pseudohypoxic signaling in pheochromocytoma and paraganglioma.
Wang Y; Liu B; Li F; Zhang Y; Gao X; Wang Y; Zhou H
Front Endocrinol (Lausanne); 2023; 14():1274239. PubMed ID: 37867526
[TBL] [Abstract][Full Text] [Related]
8. Metabolic Subtyping of Pheochromocytoma and Paraganglioma by
van Berkel A; Vriens D; Visser EP; Janssen MJR; Gotthardt M; Hermus ARMM; Geus-Oei LF; Timmers HJLM
J Nucl Med; 2019 Jun; 60(6):745-751. PubMed ID: 30413658
[TBL] [Abstract][Full Text] [Related]
9. Pheochromocytomas and paragangliomas.
Yen K; Lodish M
Curr Opin Pediatr; 2021 Aug; 33(4):430-435. PubMed ID: 34039901
[TBL] [Abstract][Full Text] [Related]
10. Performance of
Han S; Suh CH; Woo S; Kim YJ; Lee JJ
J Nucl Med; 2019 Mar; 60(3):369-376. PubMed ID: 30030341
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-210 May Be a Preoperative Biomarker of Malignant Pheochromocytomas and Paragangliomas.
Ruff SM; Ayabe RI; Malekzadeh P; Good ML; Wach MM; Gonzales MK; Tirosh A; Nilubol N; Pacak K; Kebebew E; Patel D
J Surg Res; 2019 Nov; 243():1-7. PubMed ID: 31146085
[TBL] [Abstract][Full Text] [Related]
12. New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification.
Crona J; Taïeb D; Pacak K
Endocr Rev; 2017 Dec; 38(6):489-515. PubMed ID: 28938417
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World.
Patel M; Tena I; Jha A; Taieb D; Pacak K
Front Endocrinol (Lausanne); 2021; 12():625312. PubMed ID: 33854479
[TBL] [Abstract][Full Text] [Related]
14. Molecular imaging and theranostic approaches in pheochromocytoma and paraganglioma.
Taïeb D; Pacak K
Cell Tissue Res; 2018 May; 372(2):393-401. PubMed ID: 29450723
[TBL] [Abstract][Full Text] [Related]
15. Correlation between in vivo 18F-FDG PET and immunohistochemical markers of glucose uptake and metabolism in pheochromocytoma and paraganglioma.
van Berkel A; Rao JU; Kusters B; Demir T; Visser E; Mensenkamp AR; van der Laak JA; Oosterwijk E; Lenders JW; Sweep FC; Wevers RA; Hermus AR; Langenhuijsen JF; Kunst DP; Pacak K; Gotthardt M; Timmers HJ
J Nucl Med; 2014 Aug; 55(8):1253-9. PubMed ID: 24925884
[TBL] [Abstract][Full Text] [Related]
16. Integrated PET/MRI With 68Ga-DOTATATE and 18F-FDG in Pheochromocytomas and Paragangliomas: An Initial Study.
Xu S; Pan Y; Zhou J; Ju H; Zhang Y
Clin Nucl Med; 2022 Apr; 47(4):299-304. PubMed ID: 35143455
[TBL] [Abstract][Full Text] [Related]
17. PHEOCHROMOCYTOMA: A GENETIC AND DIAGNOSTIC UPDATE.
Mercado-Asis LB; Wolf KI; Jochmanova I; Taïeb D
Endocr Pract; 2018 Jan; 24(1):78-90. PubMed ID: 29144820
[TBL] [Abstract][Full Text] [Related]
18.
Kan Y; Zhang S; Wang W; Liu J; Yang J; Wang Z
Acta Radiol; 2018 Dec; 59(12):1466-1474. PubMed ID: 29566550
[TBL] [Abstract][Full Text] [Related]
19.
Feral CC; Tissot FS; Tosello L; Fakhry N; Sebag F; Pacak K; Taïeb D
Eur J Nucl Med Mol Imaging; 2017 May; 44(5):812-821. PubMed ID: 27900521
[TBL] [Abstract][Full Text] [Related]
20. Sino-European Differences in the Genetic Landscape and Clinical Presentation of Pheochromocytoma and Paraganglioma.
Jiang J; Zhang J; Pang Y; Bechmann N; Li M; Monteagudo M; Calsina B; Gimenez-Roqueplo AP; Nölting S; Beuschlein F; Fassnacht M; Deutschbein T; Timmers HJLM; Åkerström T; Crona J; Quinkler M; Fliedner SMJ; Liu Y; Guo J; Li X; Guo W; Hou Y; Wang C; Zhang L; Xiao Q; Liu L; Gao X; Burnichon N; Robledo M; Eisenhofer G
J Clin Endocrinol Metab; 2020 Oct; 105(10):. PubMed ID: 32750708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
